Exelixis | EXEL - Current Assets


Exelixis reported $1.44B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Bayer EUR 32.91B 30M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
Eisai JPY 840.88B 50.18B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Exelixis USD 1.44B 41.03M Dec/2025
Genmab DKK 2.88B 1.59B Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Xencor USD 599.82M 81.38M Dec/2025